Related Experiment Videos
Acute Disseminated Encephalomyelitis
1Department of Neurology, Wayne State University Detroit Medical Center, 4201 Saint Antoine Street, UHC-8D, Detroit, MI 48201, USA. atselis@med.wayne.edu
Abstract:
There is no standard therapy for acute disseminated encephalomyelitis (ADEM), and treatments are based on the analogy of the pathogenesis of ADEM with that of multiple sclerosis (MS), namely an inflammatory perivenular demyelination. High-dose intravenous corticosteroids, such as methylprednisolone, at a dosage standard for MS relapses have been commonly used. Plasmapheresis, beginning with a course of four to six plasma exchanges, has also been used, particularly when intravenous methylprednisolone has failed. Intravenous immunoglobulin is a third potential therapeutic modality.
Insights
Currently, no standard therapy exists for acute disseminated encephalomyelitis (ADEM). Treatments for ADEM, including corticosteroids and plasmapheresis, are based on analogies with multiple sclerosis (MS) due to similar inflammatory demyelination.
Area of Science:
- Neurology
- Immunology
- Neuroinflammation
Background:
- Acute disseminated encephalomyelitis (ADEM) lacks a standardized treatment protocol.
- Current therapeutic strategies are extrapolated from multiple sclerosis (MS) management.
- The underlying pathology involves inflammatory perivenular demyelination.
Purpose of the Study:
- To review current therapeutic approaches for ADEM.
- To highlight the rationale behind existing treatment modalities.
- To identify potential treatment options for ADEM.
Main Methods:
- Literature review of ADEM treatment strategies.
- Analysis of therapeutic analogies with multiple sclerosis (MS).
- Examination of commonly used interventions.
Main Results:
- High-dose intravenous corticosteroids (e.g., methylprednisolone) are frequently employed, mirroring MS relapse protocols.
- Plasmapheresis, typically involving 4-6 exchanges, is considered when corticosteroid therapy is ineffective.
- Intravenous immunoglobulin (IVIG) represents another potential therapeutic option.
Conclusions:
- Treatment for ADEM is primarily based on its presumed inflammatory demyelinating nature, similar to MS.
- Corticosteroids, plasmapheresis, and IVIG are key therapeutic modalities under consideration.
- Further research may establish definitive ADEM treatment guidelines.